Control Strategies for Synthetic Therapeutic Peptide
APIs - Part I: Analytical Consideration
By Aleksander Swietlow,Harold Rode,Anita Szajek,Michael Verlander,Ivo Eggen,Brian Gregg

USP evaluates quality attributes for synthetic peptides.
The United States Pharmacopeial Convention (USP)
Therapeutic Peptides Expert Panel was formed in 2013 toevaluate quality attributes for synthetic peptides based on
currently available regulatory guidance and expectations.
Public quality standards for drug products and drug
substances are developed by USP and enforceable byFDA. This series of three articles by the Panel explores
the current manufacturing and regulatory landscape andprovides a comprehensive overview of quality attributes tobe considered for successful synthetic peptide active
pharmaceutical ingredient (API) development frommanufacturing to lot release. Specifically, the first article
IMAGE: LAGUNA DESIGN/GETTY IMAGES
covers analytical characterization methods, lot release
tests, and points to consider for synthetic peptide API manufacturers entering the market. The
second article will focus on quality control of raw materials and impurities resulting from the starting
materials used for peptide synthesis. The last article will be devoted to manufacturing processes andimpurity control of synthetic peptide APIs.
In 2012, the number of peptide drugs approved by FDA surpassed the number of approved
monoclonal antibodies and enzymes (1). These approvals serve to highlight the recent revival ofinterest in peptides, which have generally been considered to be poor drug candidates due to their
low oral bioavailability and propensity to be rapidly metabolized. However, new formulation andconjugation strategies for alternative routes of administration and overcoming short half-lives haveemerged, resulting in a larger number of marketed peptide-based drugs, some of which havereached blockbuster status (2, 3). Despite these successes, some challenges still remain. Due tovarying sizes and amino acid sequences, synthetic peptides are not easily classified into either small
molecule or biologic categories. Therein lie the regulatory challenges with peptides, especially withrespect to impurities and bioassay requirements. Understanding these challenges can help shapeand create consistency among USP’s quality standards for this growing class of drugs.
Characterization methods
Comprehensive characterization of a peptide API is required to obtain regulatory approval formarketing; the reference standard is fully characterized to ensure unequivocal identity of thematerial, its purity and API content. Besides evaluation of appearance, a selection of tests that fall
into four categories is performed: identification, assay, purity, and specific tests. The evidence
obtained from these studies also may be used in regulatory submissions, for example in Module 3 of
the Common Technical Document. Available methods and USP chapters for characterization ofpeptide APIs are summarized in Table I.

Table I: Tests used for characterization and quality control of peptide APIs*Identification. For routine identification of peptides, a high-performance liquid chromatography(HPLC) method is recommended. This method should be capable of distinguishing between thepeptide and its closely related impurities and, therefore, usually is identical to the method used todetermine impurities. The preferred identification procedure involves a comparison of retention times
between the main peak in the standard and samples, as well as a coinjection of an equal mixture ofboth, with a requirement to obtain a single peak.

Identification by mass spectrometry (MS) involves determination of the monoisotopic mass, whichshould be within ±1.0 mass units of theoretical. For peptides larger than 2 kDa, the use of highresolution instruments may be necessary and determination of the average mass may beappropriate for larger molecules. The sample concentration and solvent should be specified if
sample introduction to the instrument via direct infusion is used. MS cannot distinguish between
isomers (e.g., isoleucine and leucine) or D- and L-amino acid substitutions.
Information on amino acid (AA) composition can be obtained from amino acid analysis (AAA). The
hydrolysis protocol should be established, because those factors may significantly impact therecovery of certain amino acids.
Further characterization should involve determination of
the peptide sequence using MS-MS. At a minimum, fragmentation by collision-induced dissociation(CID) should be used, but if sequence coverage is poor, alternative fragmentation techniques suchas electron-transfer dissociation (ETD) may provide better quality data. The latter technique isparticularly useful for peptides that contain a significant number of basic residues and are highly
positively charged. Furthermore, peptides containing multiple disulfide bonds lend themselves well toETD, which can selectively cleave S-S linkages, something CID is not capable of. Prior to MS
analysis, the disulfide bonds may be reduced using suitable reducing agents, such as dithioerythritol(DTE), dithiothreitol (DTT), or tris(2-carboxyethyl)phosphine (TCEP). The linear peptide can then be
subjected to MS/MS, which will allow confirmation of sequence but not disulfide bond assignment.
For most peptides, nuclear magnetic resonance (NMR) spectroscopy should be attempted, althoughinterpretation of spectra may be challenging for peptides containing more than 10 AAs. If
comprehensive structure elucidation by NMR is not possible, then peptide mapping may be used as
an alternative. The proteases Trypsin or Lys-C are recommended for peptides containing a sufficientnumber of Arg and Lys residues, whereas for peptides containing Glu residues, Glu-C is useful. The
resulting peptide fragments are separated by HPLC and identified by MS. Peptide mapping, without
prior peptide reduction, is a potential approach for disulfide bond assignment. For routine use,peptide mapping can involve comparison with a standard.
Enantiomeric purity is determined using chiral AAA. The method is based on acid hydrolysis of thepeptide, suitable derivatization of the resulting AAs and determination of the optical isomers of theconstituent AAs by chiral gas chromatography with mass spectrometric detection (GC-MS). HPLCbased methods of chiral AAA involve pre- or post-column derivatization of AA hydrolysates, forexample using Marfey’s reagent or o-phthalaldehyde, respectively. Regardless of the hydrolysis
procedure employed, the method should be validated to account for potential racemization duringhydrolysis or subsequent derivatization. An approach that addresses this issue involves the use of
deuterated reagents (e.g., deuterium chloride [DCl])/deuterium oxide [D2O]). Substitution of the αcarbon hydrogen with deuterium allows for correction for racemization when using MS-based
detection methods.
Infrared (IR) spectrophotometry is not a useful characterization or identification tool, because spectra
tend to be dominated by water vibrations from residual water, and carbonyl bands, arising from thepeptide backbone and acetate, if present as a counterion.
The characterization of secondary or tertiary structure in aqueous solution may be relevant for
peptides, particularly in the context of determining whether a bioassay is required. The mostcommonly used methods for this purpose are circular dichroism (CD), fourier transform intrared(FTIR) analysis of amide bond vibration regions, and NMR. For the latter technique, additional
information can be obtained using deuterium exchange.

Assay. When considering assay, it is important to emphasize that many peptides are quite
hygroscopic and should be handled in a controlled-humidity environment (e.g., a glove box). Failure
to do so can lead to erroneous assay results because moisture exchange of the peptide material
with the environment can be very rapid. This process is especially fast if high surface arealyophilized material is being weighed. Establishing a sorption isotherm under ambient conditions isuseful to determine the optimum relative humidity conditions for handling the API.
Assay by HPLC is the preferred approach, assuming that a quantitative standard has beenestablished. In the absence of a quantitative standard, a “gravimetric” method, in which both thestandard and the sample are corrected for counterion content and water content (determined as partof the assay method), may be used.
Assay of peptides has traditionally been determined by quantitative AAA, which compares the peakareas of AAs in a hydrolyzed sample with the areas of the peaks for the same AAs in an externalstandard. The peptide hydrolysis procedure should be validated to ensure good recovery, and only
AAs stable to the hydrolysis conditions should be used in the calculation. Some AA sequences
containing multiple, adjacent hydrophobic residues, such as Ile, Phe, Leu and Val, may give lower
recovery than expected. Because the method involves a relatively complex sequence of operations,the results may be variable.
Assay by nitrogen content is also used routinely, most frequently determined from elemental
analysis. Kjeldahl analysis or chromatographic methods with chemiluminescence nitrogen detection
may also be used.
Only peptides containing Trp, Tyr, or Phe residues may lend themselves to assay determination
using UV absorbance measurement at 280 nm. The molar absorption coefficient can be calculated
theoretically based on knowledge of the sequence; however, the method should be independentlyvalidated using one of the techniques described previously. At lower wavelengths, common
counterions such as acetate may interfere with this assay.
Quantitative NMR is potentially useful for assay determination, although the method requires astable internal standard with signals that fully resolve from bands associated with the peptide.
Purity/related impurities determination by HPLC and control strategy. The purity of a peptide
API is usually determined using HPLC. The method should be capable of separating impurities
introduced through starting materials, process-related impurities, and impurities resulting fromdegradation of the peptide. One or more methods may be required to accomplish this objective.
When using multiple methods, it is recommended that orthogonal separation mechanisms be used.
At least one of the methods should be stability-indicating and methods should be validated per
United States Pharmacopeia < 1225> Validation of Compendial Procedures. In addition, use of LCMS compatible methods may be advantageous for the identification of impurities.
For peptides containing hydrophobic residues two reversed-phase (RP) methods may beappropriate, although alternatives, such as mixed mode RP/ion-exchange (IEX) stationary phases,
should be considered. For hydrophilic peptides, a RP method or mixed-mode RP/IEX stationary
phase may be complemented by an IEX or hydrophilic interaction chromatography (HILIC) typemethod.
A single HPLC method may be appropriate based on the sequence of the peptide and knowledge ofits potential impurities. A control strategy, built on process characterization, should be implemented
that accounts for the fate of impurities introduced with starting materials and generated during thesynthesis process and purification of the peptide. Additional, appropriately validated in-processcontrol methods may be used to ensure quality of the final product.
Non-peptide, process-related impurities, such as residual solvents and heavy metals (especially if
metal catalysts are used in the process), should also be monitored. To support the overall control
strategy, additional methods should be used, such as ion chromatography, inductively coupledplasma (ICP)-MS and NMR. The latter is particularly useful during process characterization, because
diffusion experiments allow for rapid differentiation between small-molecule organic impurities andpeptide-bound modifications.
Traces of reagents used in the process, such as trifluoroacetic acid (TFA), which is commonly usedin chromatographic purification, and inorganic fluoride [from the use of liquid hydrogen fluoride inproducts manufactured using t-butyloxycarbonyl- (Boc-) based chemistry], should also be monitored.
Specific tests. A number of tests are universally applicable to quality control testing of peptide APIs,of which the most important are counterion content and residual water content. As discussed in theassay section, the hygroscopicity of the peptide may affect the results.
APIs intended for use in injectables require bioburden and endotoxin determination. Finally, a massbalance calculation is recommended which, at a minimum, requires a summation of the percentagesof major sample components (i.e., assay [peptide content], counterion content, and water content).
The result should approach 100%.
Lot release methods
While it is, obviously, not necessary to perform all of the tests described as part of routine lot
release, the testing performed must comply with regulatory requirements for, at a minimum,
establishment of identity, purity, and assay for the peptide API. The Panel’s recommendations forthe test methods to be performed as part of lot release, as well as the quality attributes necessary forinclusion in monographs for this class of APIs, are highlighted with an asterisk in Table I.
The use of two separate identification methods is required per the International Conference onHarmonization (ICH), because a single method is rarely unequivocal. HPLC, for example, may be
used together with MS; or HPLC together with AAA, based on method complementarity
considerations. Other methods may also be necessary. An assay method based on HPLC ispreferred, but other methods may also be used if appropriately validated.
Guidance for methods and levels of impurities exist (see references provided in Table I) except for
peptide-related impurities and TFA, where no generally accepted guidance exists. Levels for theseare, therefore, set during the regulatory approval process, based on safety data for the product.
Specifications for counterion content, water content, and other specific tests are product-related andare set based on process capability and batch history.
Points to consider for API manufacturers entering the market
It should be recognized that USP monograph requirements list the minimum quality attributes thatAPIs must satisfy. For synthetic peptides, the suitability of a monograph to adequately control thequality of the API must be closely evaluated based on the manufacturing process used. While theHPLC impurities methods described in monographs are demonstrated to be stability-indicating forthe subject API and, therefore, should be expected to universally control potential degradation
products, the same is not automatically true for process-related impurities. It is necessary that
manufacturers demonstrate the suitability of the HPLC impurities methods to control actual andpotential synthetic impurities specific to their process.

Other process related residuals may include starting materials, intermediates, solvents, reagents,catalysts, and metals. They may be adequately controlled by the manufacturing process through inprocess controls and the design of the process. Synthetic peptide API manufacturers should,
therefore, assess the ability of their manufacturing process to control potential process residuals andidentify which residuals may be present at levels that require monitoring and control at the final API
stage. If the monograph methods are inadequate to control such identified process residuals, thenthe manufacturer must use additional validated methods, as appropriate. The manufacturer mustalso establish appropriate limits for process residuals not controlled by the monograph that are
justified based on the capabilities of the manufacturing process and a toxicological safetyassessment of the process residuals.
Conclusion
As a class of APIs, peptides are extremely diverse, not only in terms of their pharmacologicalproperties, but also in terms of their size, AA sequence, and potential for secondary and tertiary
structures. Possibly because of this, peptides are specifically excluded from virtually all international
guidance documents. Furthermore, while peptides are generally considered to be non-toxic, there isno generally accepted guidance for the requirements for characterization and toxicologicalcharacterization of product-related impurities. Limits proposed by the European Medicines Agency(EMA) (4) are wider than those required by the guidance in ICH Q3A, but the former are notrecognized by FDA, which therefore, considers the specifications for new peptide APIs on a case-bycase basis.
The USP hopes that, through the work of the Therapeutic Peptides Expert Panel and this series ofarticles, more consistent guidance may be provided, both for the minimum, acceptable quality
attributes for peptide API monographs, and also to industry for the characterization and quality
control testing of peptide APIs.
References
1. FDA, FDA FY2012 Innovative Drug Approvals4 (December 2012), accessed Feb. 7, 2014.
2. P. Vlieghe et al., Drug Discovery Today 15(1/2) 40-56 (2010).
3. P. Van Arnum, Pharm. Technol. 37(8) 48-50 (2013).
4. Ph. Eur., General Guidance 2034, Substances for Pharmaceutical Use (2013).

References
1. www.pharmtech.com/pharmtech/inside+usp/usp-partners-globally-for-21st-centurymedicines/articlestandard/article/detail/817347?contextcategoryid=3436
2. www.pharmtech.com/pharmtech/regulatory+beat/ema-collaborates-with-hta-assessmentnetworks/articlestandard/article/detail/834618
3. www.pharmtech.com/regulatory+watch
4. www.pharmtech.com/pharmtech/data/articlestandard/pharmtech/102014/837404/www.fda.gov/downloads/aboutfda/reportsmanualsforms/reports/ucm330859.pdf